Replies to post #62103 on Biotech Values

[genisi]

The March 2008 12% price increases also bolster sales.

[DewDiligence]

Teva Shares Rise on Blowout Copaxone Sales

http://biz.yahoo.com/ap/080430/teva_mover.html

>>
Wednesday April 30, 12:09 pm ET

NEW YORK (AP) -- Shares of Teva Pharmaceutical Industries Ltd. rose Wednesday, after the Israeli drugmaker said global sales of multiple sclerosis Copaxone rose 35 percent in the first quarter to a record $542 million.

In the U.S., sales rose 20 percent to $311 million, and abroad surged 64 percent to $231 million, though the company cautioned that international growth wouldn't be sustainable at that rate. [I.e. the dollar can’t keep falling indefinitely relative to the Euro and other currencies.]

Teva issued the data in conjunction with the release of French drugmaker Sanofi-Aventis SA's earnings report. Teva assumed responsibility for distributing Copaxone in the U.S. and Canada on April 1. [See #msg-28903325 for details.]

Shares rose 99 cents, or 2.2 percent, to $46.73 at midday.

Banc of America Securities analyst Frank Pinkerton said he expects Teva will book 55 percent of Copaxone's domestic sales, but this should increase toward 75 percent in the second quarter. It will rise again in early 2010, when it no longer reimburses Sanofi for certain marketing expenses.

Goldman Sachs analyst Randall Stanicky said Teva's share of $298 million is well above his $250 million forecast, and could add up to 4 cents per share of upside to the company's earnings estimate.

Teva will report first-quarter results early next Tuesday.
<<

[DewDiligence]

Teva Beats Non-GAAP EPS Consensus by a Penny

[GAAP EPS was bogged down by a non-recurring charge for the CoGenesys acquisition (#msg-26163282).]

http://www.reuters.com/article/marketsNews/idINL0686678520080506

>>
Tue May 6, 2008 3:22am EDT

TEL AVIV, May 6 (Reuters) - Teva Pharmaceutical Industries Ltd (TEVA), the world's largest generic drugmaker, on Tuesday reported a drop in its first-quarter net profit, weighed by a charge tied to its acquisition of CoGenesys.

Quarterly net income at the Israel-based company was $147 million, or 18 cents per share, compared with $342 million or 42 cents per share a year earlier. On an adjusted basis, which excludes the $382 million charge, Teva earned 64 cents a share. Sales rose 24 percent to $2.57 billion.

Teva was expected to earn 63 cents a share pre-exceptions on revenue of $2.53 billion, according to Reuters Estimates.

Drug sales in North America in the quarter rose 28 percent to $1.368 billion, accounting for 53 percent of sales.

Sales benefited from generic versions of heartburn drug Protonix and high blood pressure drug Lotrel, which were launched in 2007, the launch of a generic version of osteoporosis treatment Fosamax in the first quarter of 2008, and strong sales of Teva's multiple sclerosis treatment Copaxone.

Teva has 155 product applications awaiting approval by the U.S. Food and Drug Administration, for which branded sales are $98 billion a year in the United States.

Drug sales in Europe in the quarter rose 18 percent to $667 million.

Global sales of Copaxone rose 35 percent in the quarter to a record $542 million, driven by higher unit sales and price increases [#msg-28903357].

Teva President and Chief Executive Shlomo Yanai said Copaxone for the first time became the No. 1 global MS treatment.

"During the first quarter, we significantly increased investments in research and development and operations in order to support our growth plans," Yanai said.

Teva's board declared a dividend for the quarter of 0.45 shekel (13.1 cents) per share to be paid on May 29.
<<

[DewDiligence]

[MNTA] Copaxone Sales Keep Growing

2Q08 US Copaxone sales rose 17%, year-over-year, to $332M (a $1.33B annualized rate), the highest quarterly total ever. Ex-US Copaxone sales rose much more sharply (+53%) due in part to the weak dollar.

For now, the US sales number is the most pertinent one for MNTA insofar as the US is the only market to date in which MNTA and partner, Sandoz, have submitted an application to market a generic version of Copaxone.

http://biz.yahoo.com/bw/080729/20080728006442.html

Annualized 2Q08 Sales
(as reported by Teva):

US: $1.33B (59% of total), +17% YoY, +7% QoQ
ex-US: $924M (41% of total), +53% YoY, +0% QoQ
===
Total: $2.25B, +29% YoY, +4% QoQ